Taub RN - Columbia University
Mesothelioma Cancer Expert at Columbia University, New York, NY
Mesothelioma Cancer Expert - Taub RN - Current Listing of Published Papers
The following is a listing of research papers by Taub RN in the field of mesothelioma cancer.
| Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M. Peritoneal mesothelioma. Curr Treat Options Oncol. 2000 Oct;1(4):303-12. Pubmed 12057156 Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, 161 Fort Washington Avenue, New York, NY 10032, USA. |
| Taub RN, Antman KH. Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):361-6. Pubmed 9352953 Department of Medicine, Columbia University College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA. |
| Talbot SM, Rankin C, Taub RN, Balcerzak SP Jr, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH. High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Cancer. 2003 Jul 15;98(2):331-6. Pubmed 12872353 Division of Medical Oncology, Columbia University, College of Physicians and Surgeons, New York, New York, USA. |
| Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002 Jan 1;20(1):274-81. Pubmed 11773179 Alfacell Corp, 225 Belleville Ave., Bloomfield, NJ 07003, USA. [alfacell.com] |
| Borczuk AC, Taub RN, Hesdorffer M, Hibshoosh H, Chabot JA, Keohan ML, Alsberry R, Alexis D, Powell CA. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005 May 1;11(9):3303-8. Pubmed 15867227 Department of Pathology, Columbia University Medical Center, and the Columbia University Mesothelioma Center, New York, New York 10032, USA. [columbia.edu] |
| Saqi A, Yun SS, Yu GH, Alexis D, Taub RN, Powell CA, Borczuk AC. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagn Cytopathol. 2005 Aug;33(2):65-70. Pubmed 16007640 Department of Pathology, New York Presbyterian Hospital, Columbia University Medical Center, NY 10032, USA. [columbia.edu] |
